These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 32598757)

  • 1. [Follicular lymphoma: first - line selection criteria of treatment].
    Nesterova ES; Kravchenko SK; Kovrigina AM; Gemdzhian EG; Plastinina LV; Babaeva FE; Obukhova TN; Magomedova AU; Gaponova TV; Kremenetskaya AM; Vorobyev AI
    Ter Arkh; 2019 Aug; 91(8):75-83. PubMed ID: 32598757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
    Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
    Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Follicular lymphoma. High-dose immunochemotherapy with autologous blood stem cell transplantation: Results of the first prospective study in Russia].
    Nesterova ES; Kravchenko SK; Mangasarova YK; Baryakh EA; Misyurina AE; Vorobyev VI; Plastinina LV; Chernova NG; Kovrigina AM; Obukhova TN; Klyasova GA; Shevelev AA; Kostina IE; Gemdzhian EG; Gaponova TV; Vorobyev AI
    Ter Arkh; 2016; 88(7):62-71. PubMed ID: 27459617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1(1):CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models.
    Alig S; Jurinovic V; Shahrokh Esfahani M; Haebe S; Passerini V; Hellmuth JC; Gaitzsch E; Keay W; Tahiri N; Zoellner A; Rosenwald A; Klapper W; Stein H; Feller A; Ott G; Staiger AM; Horn H; Hansmann ML; Pott C; Unterhalt M; Schmidt C; Dreyling M; Alizadeh AA; Hiddemann W; Hoster E; Weigert O
    Blood Adv; 2020 Sep; 4(18):4451-4462. PubMed ID: 32941649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.
    Landsburg DJ; Falkiewicz MK; Maly J; Blum KA; Howlett C; Feldman T; Mato AR; Hill BT; Li S; Medeiros LJ; Torka P; Hernandez-Ilizaliturri F; Reddy NM; Singavi A; Fenske TS; Chavez JC; Kaplan JB; Behdad A; Petrich AM; Bast MA; Vose JM; Olszewski AJ; Costa C; Lansigan F; Gerson JN; Barta SK; Calzada O; Cohen JB; Lue JK; Amengual JE; Rivera X; Persky DO; Peace DJ; Nathan S; Cassaday RD
    J Clin Oncol; 2017 Jul; 35(20):2260-2267. PubMed ID: 28475457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma].
    Vorobyev VI; Gemdzhian EG; Dubrovin EI; Nesterova ES; Kaplanov KD; Volodicheva EM; Zherebtsova VA; Kravchenko SK
    Ter Arkh; 2019 Jul; 91(7):41-51. PubMed ID: 32598735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A comparative study of induction chemotherapy with or without autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed young medium/high risk diffuse large B cell lymphoma patients].
    Wang X; Xia B; Wang CY; Li MZ; Xu W; Yuan T; Tian C; Zhao HF; Yang HL; Zhao ZG; Wang XF; Wang YF; Yu Y; Zhang YZ
    Zhonghua Xue Ye Xue Za Zhi; 2019 Feb; 40(2):117-124. PubMed ID: 30831626
    [No Abstract]   [Full Text] [Related]  

  • 11. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
    Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
    Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
    Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Prayoonwiwat W; Numbenjapon T; Assawametha N; O'Charoen R; Swasdikul D
    Clin Lymphoma; 2000 Dec; 1(3):219-25. PubMed ID: 11707834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis.
    Pouyiourou M; Meyer A; Stroux A; Viardot A; La Rosée P; Maschmeyer G; Kämpfe D; Kahl C; Vucinic V; Monecke A; Hirt C; Weber T; Meissner J; Witzens-Harig M; Böttcher S; Schmalenberg H; Marks R; Prange-Krex G; Kroschinsky F; Hauf E; Keller U; Koch K; Klapper W; Herold M; Scholz CW;
    Ann Hematol; 2020 Dec; 99(12):2821-2829. PubMed ID: 32734548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
    van Imhoff GW; McMillan A; Matasar MJ; Radford J; Ardeshna KM; Kuliczkowski K; Kim W; Hong X; Goerloev JS; Davies A; Barrigón MDC; Ogura M; Leppä S; Fennessy M; Liao Q; van der Holt B; Lisby S; Hagenbeek A
    J Clin Oncol; 2017 Feb; 35(5):544-551. PubMed ID: 28029326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi.
    Nizzoli ME; Manni M; Ghiggi C; Pulsoni A; Musuraca G; Merli M; Califano C; Bari A; Massaia M; Conconi A; Musto P; Mannina D; Perrone T; Re F; Galimberti S; Gini G; Capponi M; Vitolo U; Usai SV; Stefani PM; Ballerini F; Liberati AM; Pennese E; Pastore D; Skrypets T; Catellani H; Marcheselli L; Federico M; Luminari S
    Hematol Oncol; 2023 Oct; 41(4):655-662. PubMed ID: 37246287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Leukemization of follicular lymphoma: The features of diagnostic and clinical course of a rare form of the disease].
    Nesterova ES; Kravchenko SK; Mangasarova YK; Plastinina LV; Dvirnyk VN; Kovrigina AM; Shchupletsova IA; Obukhova TN; Gemdzhian EG; Vorobyev IA; Vorobyev AI
    Ter Arkh; 2017; 89(7):45-50. PubMed ID: 28766540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the Effectiveness of Treatment Sequences for Older Patients With High-risk Follicular Lymphoma With a Multistate Model.
    Çağlayan Ç; Terawaki H; Ayer T; Goldstein JS; Rai A; Chen Q; Flowers C
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):300-309.e5. PubMed ID: 30686772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standard R-CHOP therapy in follicular lymphoma and diffuse large B-cell lymphoma.
    Tomita N; Takasaki H; Fujisawa S; Miyashita K; Ogusa E; Kishimoto K; Matsuura S; Sakai R; Koharazawa H; Yamamoto W; Fujimaki K; Fujita H; Ishii Y; Taguchi J; Kuwabara H; Motomura S; Ishigatsubo Y
    J Clin Exp Hematop; 2013; 53(2):121-5. PubMed ID: 23995108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and prognosis of patients with co-existing follicular lymphoma and diffuse large B-cell lymphoma components in rituximab era.
    Chen Y; Luo L; Chen L; Zheng X; Yang X; Zheng Z; Zheng J; Liu T; Yang T; Hu J
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2311-2318. PubMed ID: 36219261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.